Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib with G-CHOP in untreated follicular lymphoma
NCT06474481Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 2, open-label trial of zanubrutinib in follicular lymphoma (FL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Complete Response Rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06474481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474481.